The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Rutgers Cancer Institute expert shares evidence-based cancer information with this population and steps that can be taken now to prevent and reduce risk of disease.
The Association of American Cancer Institutes (AACI) commends President Joe Biden on his administration’s efforts to ”end cancer as we know it.”
MD Anderson and Radiopharm Theranostics today announced the launch of Radiopharm Ventures, LLC, a joint venture created to develop novel radiopharmaceutical therapeutic products for cancer.
MD Anderson researchers used extensive single-cell analysis to create a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, revealing new roles for these immune cells in cancer development and immunotherapy responses.
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial.
Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year median disease-free survival in the post-surgical treatment of patients with EGFR-mutated lung cancer, and nearly three in four patients treated with adjuvant osimertinib were disease-free at four years. The new results also indicated that the use of osimertinib reduced the risk of disease recurrence in the brain and spinal cord.
Moffitt Cancer Center is one of two institutions in the U.S. investigating a new dual checkpoint inhibitor therapy with or without stereotactic body radiation therapy for patients with Merkel cell carinoma. Results from the phase 2 clinical trial were published in The Lancet, in conjunction with a presentation at the European Society for Medical Oncology Congress.
The new patient guidelines for Marginal Zone Lymphoma guidelines are the latest in NCCN’s library of NCCN Guidelines for Patients®, published through funding from the NCCN Foundation® and available online free of charge.
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial were presented today at the European Society for Medical Oncology (ESMO) Congress 2022.
In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3% of patients with stage II–IV cutaneous squamous cell carcinoma (CSCC) saw their tumors nearly or completely disappear when treated with immunotherapy before surgery.
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2022.
RWJBarnabas Health, in partnership with Rutgers Cancer Institute of New Jersey, the state’s leading cancer center and only National Cancer Institute-Designated Comprehensive Cancer Center, announced today that it is a grantee supported through the Alliance for Equity in Cancer Care (the Alliance), an initiative funded by the Merck Foundation (the Foundation) and designed to make cancer care more equitable in the United States by helping patients living in underserved communities receive timely access to high-quality, culturally responsive care. RWJBarnabas Health and Rutgers Cancer Institute of New Jersey have been awarded a $2 million grant over five years.
New research in the September 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant prognostic benefit in objectively assessing neoadjuvant chemotherapy response in borderline resectable/locally advanced pancreatic cancer patients prior to surgery.
Stuart and Molly Sloan have pledged $78 million to support Fred Hutchinson Cancer Center. It is the largest single gift in Fred Hutch’s 47-year history.“Miracles begin in the lab, and nowhere else is that truer than at Fred Hutch,” said Stuart Sloan. “I’ve been involved with this organization for years, and during that time, I have had the opportunity to personally interact with the scientists and leaders who are making this progress possible.
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.
Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therapeutics Inc. have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression. The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments.
MD Anderson and Virogin Biotech today announced a strategic collaboration to accelerate the development of oncolytic virus therapies for advanced cancers.
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Matthew Matasar, MD, MS, as Chief of Blood Disorders at New Jersey’s leading cancer center and the only one in the state designated as a Comprehensive Cancer Center by the National Cancer Institute. In this role, he will oversee the Sections of Hematologic Malignancies; Transplant and Cell Therapy; and Benign Hematology.
El Cancer Research Institute (CRI), una organización sin fines de lucro consagrada a aprovechar la capacidad del sistema inmunitario para combatir y potencialmente curar todos los tipos de cáncer, ofrecerá su segunda Conferencia Virtual CRI de Inmunoterapia para Pacientes con Cáncer, el 22 de septiembre de 2022, de 2 a 5 p. m. (hora del este).
The Cancer Research Institute (CRI), a nonprofit organization spearheading transformative research to harness the immune system’s power to control and potentially cure all cancers, will offer its second annual CRI Virtual Immunotherapy Patient Summit in Spanish on September 22, 2022, 2-5 p.m. ET.
Thomas L. Jang, MD, MPH, FACS, chief of urologic oncology and director of the Testicular Cancer Program at Rutgers Cancer Institute of New Jersey shares what men need to know.
Amanda M. Laird, MD, FACS, chief of Endocrine Surgery and Toni Beninato, MD, MS, FACS, endocrine surgeons at Rutgers Cancer Institute of New Jersey, the state’s leading cancer center and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, and faculty in the Department of Surgery at Rutgers Robert Wood Johnson Medical School, answer some common questions about the thyroid.
September is gynecologic cancer awareness month. The empowerment of taking charge of your gynecologic health starts with having the right information and resources, knowing your body and talking openly to your doctors—and each other—about critical health issues.
People who have sickle cell disease (SCD), a genetic disorder that affects red blood cells, have reduced life expectancy and may face many challenges in their life. However, there are steps they can take to live the healthiest life possible despite this disease.
September is Childhood Cancer Awareness Month
Ira Braunschweig, MD, chief of Transplant and Cell Therapy at Rutgers Cancer Institute of New Jersey, the state’s leading cancer center and only National Cancer Institute-Designated Comprehensive Cancer Center, chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line, and director of Cell Therapy and Bone Marrow Transplantation at Robert Wood Johnson University Hospital, an RWJBarnabas facility, explains CAR T-cell immunotherapy.
Combination therapies show encouraging results in several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology (ESMO) Congress 2022, Paris, France. The studies will be presented both in-person and online on September 9-13, 2022.
Kansas Governor Laura Kelly has proclaimed September “Comprehensive Cancer Centers Awareness Month” in recognition of The University of Kansas Cancer Center becoming designated as a “Comprehensive” cancer center by the National Cancer Institute (NCI).
SEATTLE — Sept. 1, 2022 — Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news.Please note: On April 1, Fred Hutchinson Cancer Research Center merged with our care partner, Seattle Cancer Care Alliance. Our new name is Fred Hutchinson Cancer Center (Fred Hutch on subsequent references).
The Association of American Cancer Institutes (AACI) welcomes the Houston Methodist Dr. Mary and Ron Neal Cancer Center as its 105th member.
Researchers have launched a groundbreaking study utilizing autologous muscle derived progenitor cells to increase tongue strength for patients struggling with difficulty swallowing, many of whom are cancer survivors.
The human papillomavirus (HPV) vaccine is safe and effective – but it’s not for everyone. Michelle Ozbun, PhD, and her team at UNM Cancer Center published a research article earlier this year in Antimicrobial Agents and Chemotherapy in which they describe how a drug called protamine sulfate blocks HPV infection. Like a game of musical chairs among molecules, the drug molecules bind to heparan sulfate cell receptors, preventing HPV virus particles from doing so.
In a new study published in the Proceedings of the National Academy of Sciences (PNAS), Moffitt Cancer Center used mathematical and computer modeling to demonstrate the impact of skin homeostasis on driver and passenger mutations.
The National Comprehensive Cancer Network’s Oncology Research Program is collaborating with Pfizer and Myovant to address cardiovascular risk in patients with prostate cancer being treated with androgen deprivation therapy (ADT).
UC Davis Health has published one of the earliest studies assessing the use of tecovirimat to treat monkeypox (MPX) symptoms and skin lesions. The antiviral drug approved for smallpox treatment appeared to be safe and effective in 25 patients with monkeypox.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include confirmation of improving response rates in Phase I trials over the last 20 years, a novel targeted therapy combination and biomarkers of response for chimeric antigen receptor (CAR) T cell therapy in B-cell lymphomas, a combination therapy for patients with melanoma brain metastases, and new treatment options for metastatic sarcomas, HPV-driven cancers and uterine cancer.
In a new study published in the Journal of Clinical Oncology, Moffitt Cancer Center physicians, along with a team of international researchers from eight other cancer centers, report on their identification of high-risk patients with stage 3A disease and microscopic lymph node metastases who would benefit from adjuvant therapy.
MD Anderson and Erasca announced a strategic research and development collaboration to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway in cancer.
Rutgers Cancer Institute of New Jersey expert shares advice on health and wellness as students transition back into the classroom.
When a student’s parent, sibling or other key figure in their life has cancer, school attendance and performance, social relationships and behavior can all be impacted. Social workers at Rutgers Cancer Institute of New Jersey offer expert advise on helping your child cope during the upcoming school year.
Memorial Sloan Kettering Cancer Center (MSK) today announced it has received a new grant from the National Cancer institute (NCI), part of the National Institutes of Health, under the umbrella of the Cancer Moonshot, to create the MATCHES (Making Telehealth Delivery of Cancer Care at Home Effective and Safe) Telehealth Research Center at MSK, a first of its kind.
Cancer associated fibroblasts in the tumor environment have typically been associated with tumor progression and resistance to therapy, despite some studies suggesting that these fibroblasts may also sensitize cancer cells to therapy. In a new article published in Science Signaling, Moffitt Cancer Center researchers shed light on these conflicting studies and demonstrate that cancer associated fibroblasts can promote or inhibit drug sensitivity based on the type of tumor cell and the drug used for treatment.
Kimberly Leslie, MD, was awarded a four-year, $1.8 million grant from the Department of Defense (DOD) to further study high-risk uterine cancer. Her research has led her to study the differences between natural progesterone and synthetic progestins – hormones often used for birth control – and the influence of progesterone on a tumor suppressor protein called p53. The hormones, drugs and proteins, she’s learned, influence each other and the body’s cells in complex ways.
Do pediatric kidney transplant patients have better long-term outcomes when their kidney comes from living, biologically unrelated donors compared to deceased donors? A new UC Davis Health study published in the journal Pediatric Transplantation finds that they do.
The James P. Allison Institute at MD Anderson today announced the establishment of its scientific advisory board to provide strategic guidance and evaluation of its research portfolio and programs.
The targeted therapy pralsetinib was well-tolerated and demonstrated high response rates in patients with RET gene fusions regardless of tumor type, according to results from the Phase I/II ARROW trial.
Social Worker at Rutgers Cancer Institute of New Jersey shares tips for both patients and caregivers on managing grief during the cancer journey.
Individuals with blood-related cancers are more likely to experience a COVID-19 infection even after being vaccinated, a University of Kansas Cancer Center study has found.
Gerontology researchers teamed up with hematologic-oncology investigators from Brigham and Women’s Hospital and the Dana-Farber Cancer Institute to look at the association between older patients with blood cancers who were taking multiple medications and their corresponding frailty. They also created a new scale based on a list of Potentially Inappropriate Medications (PIMs) from the NCCN Guidelines® for Older Adult Oncology—called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale—and found it to be more effective at predicting frailty than conventional methods.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
